Needham Maintains Buy on Cormedix, Maintains $10 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Serge Belanger has maintained a Buy rating on Cormedix (NASDAQ:CRMD) and kept the price target at $10.
March 12, 2024 | 8:35 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Serge Belanger reaffirms a Buy rating on Cormedix, with a steady price target of $10.
The reaffirmation of a Buy rating and a $10 price target by a reputable analyst like Serge Belanger suggests a positive outlook on Cormedix's stock. This could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100